Clinical Trial Update: Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

A Phase 2 study of oral treprostinil for pulmonary hypertension associated with pulmonary fibrosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Fibrosis
• Pulmonary Hypertension

Drugs mentioned

• Orenitram (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Hypertension, Pulmonary Fibrosis | Phase 2 | Status: WITHDRAWN